Literature DB >> 3099287

Intracytoplasmic phosphorylation sites of Tac antigen (p55) are not essential for the conformation, function, and regulation of the human interleukin 2 receptor.

M Hatakeyama, S Minamoto, T Taniguchi.   

Abstract

Tac antigen, the receptor for human interleukin 2 (IL-2), contains in its intracytoplasmic region a serine residue (Ser-247) that is seemingly the predominant site of protein kinase C-mediated phosphorylation. A number of studies on growth factor receptors have suggested the importance of phosphorylation in receptor structure, function, and regulation. In this study, we generated site-directed mutations in the Tac antigen cDNA to generate mutant receptors in which Ser-247 or Thr-250, a probable site of minor phosphorylation, was replaced with another amino acid that is not accessible to phosphorylation. Study of the expression of these mutant genes in a T-lymphoid cell line has provided no evidence as to the essential role of the above-mentioned residues in determining the degree of receptor affinity, its ability for signal transduction, and phorbol ester-mediated regulation of the receptor. Our results strongly suggest the existence of an IL-2 receptor "complex" in which the Tac antigen is associated with another molecule(s) that is involved in receptor structure, function, and regulation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3099287      PMCID: PMC387198          DOI: 10.1073/pnas.83.24.9650

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Unique structure of murine interleukin-2 as deduced from cloned cDNAs.

Authors:  N Kashima; C Nishi-Takaoka; T Fujita; S Taki; G Yamada; J Hamuro; T Taniguchi
Journal:  Nature       Date:  1985 Jan 31-Feb 6       Impact factor: 49.962

2.  Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors.

Authors:  M J Zoller; M Smith
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

3.  5C6-F4, a novel 100,000-dalton rat lymphocyte activation antigen defined by monoclonal antibody.

Authors:  T Uede; H Kohda; H Yuasa; H Osawa; T Diamantstein; J Yodoi; Y Ishii; K Kikuchi
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

4.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

5.  Mechanism of tumor promoter inhibition of cellular binding of epidermal growth factor.

Authors:  L S Lee; I B Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

6.  Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane.

Authors:  T Hunter; N Ling; J A Cooper
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

7.  Tumor-promoting phorbol diesters mediate phosphorylation of the epidermal growth factor receptor.

Authors:  R J Davis; M P Czech
Journal:  J Biol Chem       Date:  1984-07-10       Impact factor: 5.157

8.  Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells.

Authors:  T Uchiyama; T Hori; M Tsudo; Y Wano; H Umadome; S Tamori; J Yodoi; M Maeda; H Sawami; H Uchino
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

9.  Inhibition of insulin receptor binding by phorbol esters.

Authors:  P Thomopoulos; U Testa; M F Gourdin; C Hervy; M Titeux; W Vainchenker
Journal:  Eur J Biochem       Date:  1982-12-15

10.  Interleukin 2 inhibits in vitro growth of human T cell lines carrying retrovirus.

Authors:  K Sugamura; S Nakai; M Fujii; Y Hinuma
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  8 in total

1.  Expression and modulation of cell surface determinants on human adult and neonatal monocytes.

Authors:  P A Marwitz; E Van Arkel-Vigna; G T Rijkers; B J Zegers
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

2.  Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.

Authors:  Jennifer A A Gubbels; Brian Gadbaw; Ilia N Buhtoiarov; Sachi Horibata; Arvinder K Kapur; Dhara Patel; Jacquelyn A Hank; Stephen D Gillies; Paul M Sondel; Manish S Patankar; Joseph Connor
Journal:  Cancer Immunol Immunother       Date:  2011-07-27       Impact factor: 6.968

3.  c-fos gene induction by interleukin 2: identification of the critical cytoplasmic regions within the interleukin 2 receptor beta chain.

Authors:  M Hatakeyama; A Kawahara; H Mori; H Shibuya; T Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

Review 4.  Interleukin-2 receptor signaling in regulatory T cell development and homeostasis.

Authors:  Matthew A Burchill; Jianying Yang; Kieng B Vang; Michael A Farrar
Journal:  Immunol Lett       Date:  2007-09-14       Impact factor: 3.685

5.  Transmembrane signaling of interleukin 2 receptor. Conformation and function of human interleukin 2 receptor (p55)/insulin receptor chimeric molecules.

Authors:  M Hatakeyama; T Doi; T Kono; M Maruyama; S Minamoto; H Mori; M Kobayashi; T Uchiyama; T Taniguchi
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

6.  The integrity of the conserved 'WS motif' common to IL-2 and other cytokine receptors is essential for ligand binding and signal transduction.

Authors:  T Miyazaki; M Maruyama; G Yamada; M Hatakeyama; T Taniguchi
Journal:  EMBO J       Date:  1991-11       Impact factor: 11.598

7.  Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN-beta gene regulatory elements.

Authors:  T Fujita; J Sakakibara; Y Sudo; M Miyamoto; Y Kimura; T Taniguchi
Journal:  EMBO J       Date:  1988-11       Impact factor: 11.598

Review 8.  Dysregulation of growth factor-receptor system in cellular transformation.

Authors:  M Hatakeyama; T Taniguchi
Journal:  Jpn J Cancer Res       Date:  1988-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.